The imperative to develop pharmacological strategies that increase healthspan, reduce years spent with disability, and prevent and treat age-related diseases and conditions is well recognized (1). The current approach to drug development is to target individual diseases and undertake clinical trials in participants without significant comorbidities or disabilities. Most patients who receive drug therapies in real life tend to be older people with multimorbidity, frailty, and polypharmacy and thus are not well served by this drug discovery model. Even in those older people with a single phenotypic disease, the situation is complicated by the fact that their disease will often have a...

中文翻译：

---

开发针对老龄化和与年龄相关的疾病的新药的组织创新。

制定药理学策略以增加健康寿命、减少残疾年限以及预防和治疗与年龄相关的疾病和病症的必要性已得到广泛认可 (1)。目前的药物开发方法是针对个别疾病并在没有严重合并症或残疾的参与者中进行临床试验。大多数在现实生活中接受药物治疗的患者往往是患有多种疾病、身体虚弱和服用多种药物的老年人，因此这种药物发现模型不能很好地服务。即使在那些患有单一表型疾病的老年人中，由于他们的疾病通常会出现...